CD20 and CD3 Bispecific Target Combination (CD20/CD3)

Molecular Classification

Transmembrane protein (CD20), MS4A family (CD20), Immune cell signaling protein (CD20), Multimeric protein complex (CD3), Immune receptor (CD3), Signal transduction co-receptor (CD3)

Other Names

B-lymphocyte antigen CD20, MS4A1, T-cell receptor CD3 complex, CD3 complex, CD20/CD3 bispecifics

Disease Roles

Cancer (B-cell malignancies, e.g., lymphoma, leukemia) (CD20)Autoimmune diseases (e.g., multiple sclerosis) (CD20)Cancer (T-cell engagement, immunotherapy) (CD3)

CD20 and CD3 Bispecific Target Combination Overview

CD20 is a multi-pass transmembrane protein encoded by the MS4A1 gene and expressed on most B cells. It is a key target for monoclonal antibody therapies in B cell malignancies and some autoimmune conditions. It may help regulate B cell activation and calcium signaling, but its precise physiological role remains partially unresolved[1][2][8]. CD3 refers to the multisubunit complex associated with the T-cell receptor on all T cells. It is essential for TCR-mediated signaling and T-cell activation. CD3-binding drugs can alter immune function and have been used both to activate and deplete T cells in various clinical settings[6][7]. "CD20/CD3" is a shorthand used in immunotherapy for bispecific antibodies that bind both CD20 (on B cells) and CD3 (on T cells), bringing T cells into close proximity to malignant B cells to trigger cytotoxic responses. There is no single molecule with this name; the terminology signifies a drug mechanism, not a molecular entity[1]. If you require information structured for a single canonical molecule or receptor, you must specify either "CD20" or "CD3"; "CD20/CD3" as a target is ambiguous and not formally correct.

Mechanism of Action

CD20/CD3 bispecific antibodies function by simultaneously binding to CD20 on B cells and CD3 on T cells. This mechanism brings T cells into close proximity to malignant B cells, leading to the recruitment and activation of T cells via CD3 to trigger redirected cytotoxicity against CD20-expressing target cells.

Biological Functions

Regulates B cell activation and signaling (CD20)

May contribute to calcium flux in B cells (CD20)

Maintains resting B cell state (CD20)

Interacts with other surface molecules (BCR, CD19, CXCR4, CD40) (CD20)

Essential co-receptor for T cell activation (CD3)

Transduces signals from the T-cell receptor following antigen recognition (CD3)

Initiates intracellular phosphorylation cascades and ITAM-mediated signal transduction (CD3)

Mediates T-cell mediated killing of B cells (CD20/CD3 combination)

Disease Associations

Cancer (B-cell malignancies, e.g., lymphoma, leukemia) (CD20)

Autoimmune diseases (e.g., multiple sclerosis) (CD20)

Cancer (T-cell engagement, immunotherapy) (CD3)

Autoimmune diseases (CD3)

Infection (plays a central role in T-cell immunity) (CD3)

Safety Considerations

Immunosuppression (CD20-targeting agents)
Risk of infection (CD20-targeting agents)
Infusion reactions (CD20-targeting agents)
Depletion of normal B cells (CD20-targeting agents)
Cytokine release syndrome (CD3-targeting agents and CD20/CD3 bispecifics)
T cell depletion (CD3-targeting agents)
Immune toxicity (CD3-targeting agents)
Heightened risk of neurotoxicity (CD20/CD3 bispecifics)

Interacting Drugs

Rituximab (CD20)

Ofatumumab (CD20)

Obinutuzumab (CD20)

Ocrelizumab (CD20)

Muromonab-CD3 (OKT3) (CD3)

Teplizumab (CD3)

Mosunetuzumab (CD20/CD3 bispecific)

Glofitamab (CD20/CD3 bispecific)

Associated Biomarkers

Biomarker
CD20 expression on B cells (for selection and efficacy assessment in B-cell malignancies)
CD3 as a pan-T cell marker (for flow cytometry and tissue immunophenotyping)